Loading...

Kobayashi Pharmaceutical

OTCPK:KBYP.F
Snowflake Description

Excellent balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KBYP.F
OTCPK
¥773B
Market Cap
  1. Home
  2. US
  3. Household
Company description

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
KBYP.F Share Price and Events
7 Day Returns
0%
OTCPK:KBYP.F
0.4%
US Personal Products
0.4%
US Market
1 Year Returns
-
OTCPK:KBYP.F
0.7%
US Personal Products
6.8%
US Market
KBYP.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kobayashi Pharmaceutical (KBYP.F) 0% 0% - - - -
US Personal Products 0.4% 1.1% 26.7% 0.7% 19.5% 39.6%
US Market 0.4% 2.6% 11% 6.8% 38.1% 45.7%
1 Year Return vs Industry and Market
  • No trading data on KBYP.F.
  • No trading data on KBYP.F.
Price Volatility
KBYP.F
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Kobayashi Pharmaceutical's competitors could be found in our database.

KBYP.F Value

 Is Kobayashi Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Kobayashi Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Kobayashi Pharmaceutical.

OTCPK:KBYP.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:KBYP.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.675 (1 + (1- 30.86%) (0.13%))
0.782
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for OTCPK:KBYP.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Kobayashi Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:KBYP.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 7.5%)
2019 18,700.00 Analyst x3 17,395.67
2020 14,407.50 Analyst x4 12,467.74
2021 17,377.50 Analyst x4 13,988.98
2022 23,200.00 Analyst x1 17,373.47
2023 24,800.00 Analyst x1 17,276.26
2024 26,161.21 Est @ 5.49% 16,953.35
2025 27,380.62 Est @ 4.66% 16,505.95
2026 28,498.24 Est @ 4.08% 15,981.41
2027 29,545.91 Est @ 3.68% 15,413.24
2028 30,548.22 Est @ 3.39% 14,824.57
Present value of next 10 years cash flows ¥158,180.65
OTCPK:KBYP.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥30,548.22 × (1 + 2.73%) ÷ (7.5% – 2.73%)
¥658,183.47
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥658,183.47 ÷ (1 + 7.5%)10
¥319,406.04
OTCPK:KBYP.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥158,180.65 + ¥319,406.04
¥477,586.69
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥477,586.69 / 78.88
¥6054.9
OTCPK:KBYP.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:KBYP.F represents 0.00663x of TSE:4967
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00663x
Value per Share
(Listing Adjusted, USD)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 6,054.90 x 0.00663
$40.16
Value per share (USD) From above. $40.16
Current discount Discount to share price of $65.00
= -1 x ($65.00 - $40.16) / $40.16
-61.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Kobayashi Pharmaceutical is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kobayashi Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kobayashi Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:KBYP.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥228.04
TSE:4967 Share Price ** TSE (2019-01-18) in JPY ¥9800
United States of America Personal Products Industry PE Ratio Median Figure of 19 Publicly-Listed Personal Products Companies 24.79x
United States of America Market PE Ratio Median Figure of 3,072 Publicly-Listed Companies 18.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kobayashi Pharmaceutical.

OTCPK:KBYP.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4967 Share Price ÷ EPS (both in JPY)

= 9800 ÷ 228.04

42.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kobayashi Pharmaceutical is overvalued based on earnings compared to the US Personal Products industry average.
  • Kobayashi Pharmaceutical is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Kobayashi Pharmaceutical's expected growth come at a high price?
Raw Data
OTCPK:KBYP.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 42.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
6.7%per year
United States of America Personal Products Industry PEG Ratio Median Figure of 8 Publicly-Listed Personal Products Companies 1.78x
United States of America Market PEG Ratio Median Figure of 2,107 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

OTCPK:KBYP.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 42.97x ÷ 6.7%

6.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kobayashi Pharmaceutical is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Kobayashi Pharmaceutical's assets?
Raw Data
OTCPK:KBYP.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥2,102.47
TSE:4967 Share Price * TSE (2019-01-18) in JPY ¥9800
United States of America Personal Products Industry PB Ratio Median Figure of 45 Publicly-Listed Personal Products Companies 5.26x
United States of America Market PB Ratio Median Figure of 5,176 Publicly-Listed Companies 1.91x
OTCPK:KBYP.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4967 Share Price ÷ Book Value per Share (both in JPY)

= 9800 ÷ 2,102.47

4.66x

* Primary Listing of Kobayashi Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kobayashi Pharmaceutical is good value based on assets compared to the US Personal Products industry average.
X
Value checks
We assess Kobayashi Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Kobayashi Pharmaceutical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KBYP.F Future Performance

 How is Kobayashi Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kobayashi Pharmaceutical expected to grow at an attractive rate?
  • Kobayashi Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Kobayashi Pharmaceutical's earnings growth is positive but not above the United States of America market average.
  • Kobayashi Pharmaceutical's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:KBYP.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:KBYP.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 6.7%
OTCPK:KBYP.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 4.7%
United States of America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 18.9%
United States of America Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:KBYP.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:KBYP.F Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 216,900 29,300 26,700 1
2022-12-31 206,400 27,700 25,100 1
2021-12-31 190,158 26,744 21,966 6
2020-12-31 182,867 24,730 20,998 6
2019-12-31 175,177 25,261 20,025 6
OTCPK:KBYP.F Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 167,479 20,007 18,023
2018-09-30 164,876 18,132
2018-06-30 162,132 19,577 16,455
2018-03-31 159,727 16,229
2017-12-31 156,761 22,350 15,863
2016-12-31 152,654 21,463 15,333
2016-09-30 148,008 18,058 15,561
2016-06-30 144,007 15,801
2016-03-31 137,211 14,329 13,466

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kobayashi Pharmaceutical's earnings are expected to grow by 6.7% yearly, however this is not considered high growth (20% yearly).
  • Kobayashi Pharmaceutical's revenue is expected to grow by 4.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:KBYP.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Kobayashi Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KBYP.F Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 343.50 343.50 343.50 1.00
2022-12-31 322.90 322.90 322.90 1.00
2021-12-31 279.78 304.90 259.26 6.00
2020-12-31 267.41 284.30 252.93 6.00
2019-12-31 254.77 263.70 240.70 6.00
OTCPK:KBYP.F Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 228.04
2018-09-30 229.53
2018-06-30 208.41
2018-03-31 205.85
2017-12-31 201.31
2016-12-31 191.42
2016-09-30 192.85
2016-06-30 194.92
2016-03-31 165.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Kobayashi Pharmaceutical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Kobayashi Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kobayashi Pharmaceutical has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KBYP.F Past Performance

  How has Kobayashi Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kobayashi Pharmaceutical's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kobayashi Pharmaceutical's year on year earnings growth rate has been positive over the past 5 years.
  • Kobayashi Pharmaceutical's 1-year earnings growth exceeds its 5-year average (13.6% vs 9.2%)
  • Kobayashi Pharmaceutical's earnings growth has not exceeded the US Personal Products industry average in the past year (13.6% vs 21.4%).
Earnings and Revenue History
Kobayashi Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kobayashi Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KBYP.F Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 167,479.00 18,023.00 68,119.00 7,031.00
2018-09-30 164,876.00 18,132.00 66,762.00 7,239.00
2018-06-30 162,132.00 16,455.00 66,070.00 7,239.00
2018-03-31 159,727.00 16,229.00 64,906.00 7,239.00
2017-12-31 156,761.00 15,863.00 63,540.00 7,239.00
2016-12-31 152,654.00 15,333.00 58,018.00 9,909.00
2016-09-30 148,008.00 15,561.00 59,206.00 5,788.00
2016-06-30 144,007.00 15,801.00 56,081.00 5,788.00
2016-03-31 137,211.00 13,466.00 54,121.00 5,788.00
2015-12-31 135,798.00 14,230.00 51,882.00 5,289.00
2015-09-30 133,385.00 13,008.00 50,362.00 5,289.00
2015-06-30 131,144.00 12,915.00 49,227.00 5,289.00
2015-03-31 128,344.00 12,448.00 48,963.00 5,289.00
2014-12-31 128,721.00 12,730.00 49,511.00 4,930.00
2014-09-30 127,574.00 11,808.00 49,610.00 4,930.00
2014-06-30 127,256.00 11,760.00 49,421.00 4,930.00
2014-03-31 127,293.00 12,307.00 48,662.00 4,930.00
2013-12-31 122,430.00 10,819.00 47,374.00 4,544.00
2013-09-30 121,526.00 11,009.00 46,765.00 4,544.00
2013-06-30 120,661.00 11,357.00 46,214.00 4,544.00
2013-03-31 121,532.00 12,176.00 47,056.00 4,544.00
2012-12-31 123,258.00 13,859.00 48,658.00 4,385.00
2012-09-30 125,396.00 12,696.00 50,559.00 4,385.00
2012-06-30 129,379.00 12,107.00 52,124.00 4,385.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Kobayashi Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Kobayashi Pharmaceutical used its assets less efficiently than the US Personal Products industry average last year based on Return on Assets.
  • Kobayashi Pharmaceutical has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Kobayashi Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kobayashi Pharmaceutical has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KBYP.F Health

 How is Kobayashi Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kobayashi Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kobayashi Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kobayashi Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kobayashi Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 150.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kobayashi Pharmaceutical Company Filings, last reported 3 months ago.

OTCPK:KBYP.F Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 166,248.00 1,031.00 82,756.00
2018-09-30 165,080.00 834.00 71,393.00
2018-06-30 159,551.00 827.00 73,297.00
2018-03-31 154,037.00 747.00 75,893.00
2017-12-31 153,810.00 776.00 73,290.00
2016-12-31 143,319.00 829.00 63,673.00
2016-09-30 141,975.00 853.00 61,865.00
2016-06-30 141,376.00 877.00 64,438.00
2016-03-31 142,023.00 865.00 65,928.00
2015-12-31 147,618.00 860.00 60,996.00
2015-09-30 146,891.00 895.00 63,632.00
2015-06-30 142,697.00 784.00 61,100.00
2015-03-31 139,609.00 635.00 62,949.00
2014-12-31 133,599.00 656.00 53,839.00
2014-09-30 128,052.00 700.00 53,275.00
2014-06-30 125,614.00 717.00 51,688.00
2014-03-31 126,952.00 773.00 55,451.00
2013-12-31 123,810.00 302.00 47,178.00
2013-09-30 120,781.00 308.00 46,249.00
2013-06-30 117,082.00 347.00 44,375.00
2013-03-31 114,870.00 429.00 47,368.00
2012-12-31 110,355.00 507.00 38,354.00
2012-09-30 107,881.00 592.00 38,253.00
2012-06-30 105,150.00 683.00 51,539.00
  • Kobayashi Pharmaceutical's level of debt (0.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.2% vs 0.6% today).
  • Debt is well covered by operating cash flow (1940.5%, greater than 20% of total debt).
  • Kobayashi Pharmaceutical earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Kobayashi Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kobayashi Pharmaceutical has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KBYP.F Dividends

 What is Kobayashi Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.69%
Current annual income from Kobayashi Pharmaceutical dividends. Estimated to be 0.78% next year.
If you bought $2,000 of Kobayashi Pharmaceutical shares you are expected to receive $14 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Kobayashi Pharmaceutical's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.41%).
  • Kobayashi Pharmaceutical's dividend is below the markets top 25% of dividend payers in United States of America (3.63%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:KBYP.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:KBYP.F Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 96.00 1.00
2022-12-31 90.00 1.00
2021-12-31 78.20 5.00
2020-12-31 74.60 5.00
2019-12-31 70.80 5.00
OTCPK:KBYP.F Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-03-28 68.000 0.720
2019-01-31 68.000 0.767
2018-11-13 61.000 0.837
2018-10-29 61.000 0.834
2018-08-07 61.000 0.788
2018-07-31 61.000 0.724
2018-03-29 60.000 0.646
2018-02-02 60.000 0.858
2017-11-14 54.000 0.743
2017-10-30 56.000 0.824
2017-08-08 54.000 0.827
2017-07-31 54.000 0.807
2017-04-28 52.000 0.783
2017-02-01 52.000 0.962
2016-11-09 49.000 0.976
2016-11-01 49.000 0.957
2016-05-09 48.000 1.014
2016-02-05 48.000 1.019
2016-01-25 47.000 0.937
2015-11-09 47.000 0.970
2015-10-29 47.000 1.013
2015-07-27 46.000 1.006
2015-06-26 46.000 1.018
2015-04-30 46.000 1.130
2015-02-06 43.500 1.026
2015-01-29 43.500 1.108
2014-11-07 43.500 1.239
2014-10-30 43.500 1.293
2014-06-27 43.000 1.312
2014-04-30 43.000 1.322
2013-11-01 42.000 1.482
2013-05-01 41.000 1.547
2013-01-29 41.000 1.770
2012-11-02 39.000 1.867
2012-07-26 39.000 1.862
2012-06-28 39.000 1.804
2012-05-01 39.000 1.839
2012-02-08 35.000 1.749
2012-01-30 35.000 1.786
2011-11-10 35.000 1.771
2011-10-26 35.000 1.782
2011-07-26 35.000 1.761
2011-06-29 35.000 1.720
2011-05-06 35.000 1.817
2011-02-08 33.000 1.733
2011-01-31 33.000 1.689
2010-11-10 33.000 1.743
2010-10-27 33.000 1.754
2010-06-29 33.000 1.778
2010-05-07 33.000 1.780
2010-02-10 29.000 1.548
2010-01-29 29.000 1.621
2009-11-11 29.000 1.541
2009-10-30 29.000 1.519
2009-05-07 29.000 1.568
2009-04-20 29.000 1.805

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kobayashi Pharmaceutical is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • Kobayashi Pharmaceutical is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Kobayashi Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Kobayashi Pharmaceutical's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • No need to calculate the sustainability of Kobayashi Pharmaceutical's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Kobayashi Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kobayashi Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kobayashi Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KBYP.F Management

 What is the CEO of Kobayashi Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kazumasa Kobayashi
COMPENSATION ¥205,000,000
AGE 79
TENURE AS CEO 14.8 years
CEO Bio

Mr. Kazumasa Kobayashi has been the Chairman of the Board and Chief Executive Officer of Kobayashi Pharmaceutical Co. LTD. since June 2004. Mr. Kobayashi served as the President of KOBAYASHI Pharmaceutical Co Ltd. He served as a Director of MediPal Holdings Corporation.

CEO Compensation
  • Kazumasa's compensation has been consistent with company performance over the past year.
  • Kazumasa's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Kobayashi Pharmaceutical management team in years:

12.8
Average Tenure
61
Average Age
  • The average tenure for the Kobayashi Pharmaceutical management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Kazumasa Kobayashi

TITLE
Chairman of the Board & CEO
COMPENSATION
¥205M
AGE
79
TENURE
14.8 yrs

Akihiro Kobayashi

TITLE
President
AGE
47
TENURE
5.8 yrs

Satoshi Yamane

TITLE
Senior MD
AGE
58
TENURE
12.8 yrs

Takashi Tsujino

TITLE
Executive VP
AGE
69

Susumu Horiuchi

TITLE
MD, Senior GM of Sales Division & Executive Director
AGE
61

Fujito Owaki

TITLE
Senior GM of Health Division

Tetsuji Nishioka

TITLE
Senior GM of Manufacturing Division & Executive Officer

Toshio Namba

TITLE
Executive Officer and Senior GM of Reliability & Assurance

Kenichiro Tanaka

TITLE
Deputy Senior GM of Sales Division & Executive Officer

Kazuhito Miyanishi

TITLE
Senior GM of International Business Division & Executive Officer
Board of Directors Tenure

Average tenure and age of the Kobayashi Pharmaceutical board of directors in years:

5.8
Average Tenure
64
Average Age
  • The tenure for the Kobayashi Pharmaceutical board of directors is about average.
Board of Directors

Kazumasa Kobayashi

TITLE
Chairman of the Board & CEO
COMPENSATION
¥205M
AGE
79
TENURE
14.8 yrs

Yutaka Kobayashi

TITLE
Vice Chairman of the Board
COMPENSATION
¥134M
AGE
73
TENURE
5.8 yrs

Akihiro Kobayashi

TITLE
President
AGE
47
TENURE
5.8 yrs

Satoshi Yamane

TITLE
Senior MD
AGE
58
TENURE
12.8 yrs

Takashi Tsujino

TITLE
Executive VP
AGE
69

Susumu Horiuchi

TITLE
MD, Senior GM of Sales Division & Executive Director
AGE
61
TENURE
4.8 yrs

Haruo Tsuji

TITLE
Outside Director
AGE
86
TENURE
10.8 yrs

Kunio Ito

TITLE
Outside Director
AGE
67
TENURE
5.8 yrs

Kaori Sasaki

TITLE
Outside Director
AGE
59
TENURE
2.8 yrs

Ryuji Sakai

TITLE
Outside Audit & Supervisory Board Member
AGE
61
TENURE
13.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Kobayashi Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kobayashi Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KBYP.F News

Simply Wall St News

KBYP.F Company Info

Description

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company operates through four segments: Domestic Consumer Products Business, Overseas Consumers Products Business, Direct Marketing Business, and Other Business. The Domestic Consumer Products segment offers products that include Kurocure, a remedy for dark and rough spots on elbows and knees; Hishimore, a medication for dry skin; Nightmin Nasal Respiration Tape, a product that helps to breathe through nose; Sawaday Kaoru Stick Aroma, a home fragrance for aromatic oils; Keshimin Cream EX, a prescription cream for spots; and Bioil, a skincare oil. This segment also offers Eyebon, an eye wash solution with corneal healing and protective ingredients; Bisrat Gold, an obesity therapeutic drug; Inochi no Haha A, a women’s health medicine; Chikunain, a sinusitis medicine; Dusmock, a Kampo medicine that ameliorates persistent coughing and bronchitis; Sarasaty, a panty liner; Bluelet, a toilet bowl cleaner and freshener in the household products category; Keshimin, a skincare product for spots; and Madame Juju, a skincare cream in the skincare category. The Overseas Consumer Products segment provides products, such as body warmers; Netsusama sheet, a cooling gel sheet for the forehead; and Ammeltz, a topical anti-inflammatory. The Direct Marketing Business segment engages in the mail-order sale of nutritional supplements, skincare products, and other products by telephonic orders and online. The Other Business segment is involved in the transportation business; manufacture and distribution of plastic containers; insurance agency operations; and real estate management, and advertising planning and production activities. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.

Details
Name: Kobayashi Pharmaceutical Co., Ltd.
KBYP.F
Exchange: OTCPK
Founded: 1886
¥6,903,504,666
78,876,063
Website: http://www.kobayashi.co.jp
Address: Kobayashi Pharmaceutical Co., Ltd.
KDX Kobayashi Doshomachi Building,
4-4-10, Doshomachi,
Osaka,
541-0045,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4967 Common Stock The Tokyo Stock Exchange JP JPY 20. Apr 1999
OTCPK KBYP.F Common Stock Pink Sheets LLC US USD 20. Apr 1999
DB KOY Common Stock Deutsche Boerse AG DE EUR 20. Apr 1999
Number of employees
Current staff
Staff numbers
3,271
Kobayashi Pharmaceutical employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 00:19
End of day share price update: 2019/01/18 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.